© 1992 British Society for Rheumatology
other |
LONG-TERM SECOND-LINE TREATMENT: A PROSPECTIVE DRUG SURVIVAL STUDY
*Departments of Rheiimatology University Hospital Nijmegen, The Netherlands
Departments of Medical Statistics University Hospital Nijmegen, The Netherlands
Departments of Rheumatology, University Hospital Groningen The Netherlands
Correspondence to:
Correspondence to Dr M. Wijnands, Department of Rheumatology, University Hospital Nijmegen, P. 0. Box 9101, 6500 HB, The Netherlands
The long-term use of second-line antirheumatic drugs was prospectively studied in a consecutive sample of 245 patients with recently diagnosed rheumatoid arthritis. A survival analysis was done in which treatment termination due to side-effects and to insufficient therapeutic effect were used as index causes. Cumulative drug ‘survival’ of aurothioglucose with treatment termination due to toxicity was significantly less compared with hydroxychioroquine. With regard to lack of efficacy as index cause, the administration time of hydroxychloroquine was significantly less than that of either aurothioglucose or sulphasalazine. Treatment termination due to lack of efficacy or combined insufficient therapeutic response and toxicity proved to be influenced by the initial disease activity and by the rank order of prescription.
KEY WORDS: DMARD, Survival analysis, Toxicity, Rheumatoid arthritis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. L. Hyrich, K. D. Watson, A. J. Silman, D. P. M. Symmons, and The BSR Biologics Register Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Rheumatology, December 1, 2006; 45(12): 1558 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Aletaha, T Stamm, T Kapral, G Eberl, J Grisar, K P Machold, and J S Smolen Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study Ann Rheum Dis, October 1, 2003; 62(10): 944 - 951. [Abstract] [Full Text]
|
|
|
|
|
|
D. Aletaha and J. S. Smolen The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses Rheumatology, December 1, 2002; 41(12): 1367 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barrera, A. van der Maas, A. E. van Ede, B. A. L. M. Kiemeney, R. F. J. M. Laan, L. B. A. van de Putte, and P. L. C. M. van Riel Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-{alpha} antibody compared with methotrexate in long-standing rheumatoid arthritis Rheumatology, April 1, 2002; 41(4): 430 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Sokka and P Hannonen Utility of disease modifying antirheumatic drugs in "sawtooth" strategy. A prospective study of early rheumatoid arthritis patients up to 15 years Ann Rheum Dis, October 1, 1999; 58(10): 618 - 622. [Abstract] [Full Text]
|
|
|
|
|
|
J A. Aviña-Zubieta, G. Galindo-Rodriguez, S. Newman, M. E Suarez-Almazor, and A. S Russell Long term effectiveness of antimalarial drugs in rheumatic diseases Ann Rheum Dis, October 1, 1998; 57(10): 582 - 587. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. D. Schiff and T. D. Rucker Computerized Prescribing: Building the Electronic Infrastructure for Better Medication Usage JAMA, April 1, 1998; 279(13): 1024 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Modifying disease in rheumatoid arthritis DTB, January 1, 1998; 36(1): 3 - 6. [Abstract] [Full Text] [PDF]
|
|